Clinical Trials Logo

Atypical Parkinson Disease clinical trials

View clinical trials related to Atypical Parkinson Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03552484 Completed - Clinical trials for Multiple System Atrophy

In-Home Care for Patients With PSP and Related Disorders

Start date: May 30, 2018
Phase: N/A
Study type: Interventional

Progressive Supranuclear Palsy and related disorders (PRD) are debilitating, costly, and understudied conditions. Improving access to comprehensive, specialized, in-home patient care offers the potential to minimize the downward spiral of morbidity and preventable healthcare utilization. The aim of this study is to test whether and to what degree an interdisciplinary home visit program will improve patient- and caregiver-reported outcomes, and to identify unmet needs in this population.

NCT ID: NCT02994719 Recruiting - Parkinson's Disease Clinical Trials

Gait Analysis in Neurological Disease

Start date: March 1, 2016
Phase:
Study type: Observational

The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

NCT ID: NCT02018406 Recruiting - Cerebral Palsy Clinical Trials

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

Start date: July 5, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of our study is to determine the safety and efficacy of the combination of erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with neurological diseases. To be specific, our clinical study is expected that the combination injection of EPO and G-CSF shows neurotrophic and neuroprotective effects by facilitating endogenous repair process in patients with neurological diseases including stroke, cerebral palsy, or atypical parkinsonism. Therefore, we will apply our original treatment technique in patients with neurological diseases, which is expected to overcome current ethical and technical limitations of less evidenced functional recovery, hematological changes, and side effects. Eventually, We will establish a comprehensive clinical background about neurotrophic and neuroprotective effects of this hematopoietic growth factors therapy.